Hikma Pharmaceuticals Plc
28 November 2005
HIKMA PHARMACEUTICALS PLC
28 November 2005
Renewal of Contract
Hikma Pharmaceuticals PLC announces the renewal of the sales contract with the
Department of Veterans Affairs, an agency of the government of the United States
of America, for the supply of lisinopril.
This renewal represents the exercise of the 3rd Option Year for the contract
with a contract period between 21 December 2005 and 20 December 2006. All other
terms and conditions of the contract, including pricing, remain unchanged.
ENQUIRIES:
Hikma Pharmaceuticals PLC
Bassam Kanaan (Chief Financial Officer) +962 6 580 2900
Brunswick
Jon Coles +44 207 404 5959
Wendel Verbeek
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.